D. E. Shaw & Co., Inc. Krystal Biotech, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $122 Billion
- Q4 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 7,427 shares of KRYS stock, worth $1.14 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,427
Previous 9,346
20.53%
Holding current value
$1.14 Million
Previous $1.7 Million
31.55%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding KRYS
# of Institutions
297Shares Held
24.3MCall Options Held
388KPut Options Held
233K-
Black Rock Inc. New York, NY3.95MShares$605 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.88MShares$441 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.63MShares$403 Million6.0% of portfolio
-
State Street Corp Boston, MA1.28MShares$196 Million0.01% of portfolio
-
Capital World Investors Los Angeles, CA879KShares$135 Million0.02% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $3.93B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...